Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy
- PMID: 1419639
- PMCID: PMC1978003
- DOI: 10.1038/bjc.1992.388
Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy
Abstract
Glutathione S-transferase (GST) isoenzyme composition, isoenzyme quantities and enzymatic activity were investigated in benign (n = 4) ovarian tumours and malignant ovarian tumours, before (n = 20) and after (n = 16) chemotherapy. Enzymatic activity of GST in cytosols was measured by determining 1-chloro-2,4-dinitrobenzene conjugation with glutathione, cytosolic GST subunits were determined by wide pore reversed phase HPLC, using a S-hexylglutathione-agarose affinity column, and isoelectric focussing. Both GST activity and GST pi amount were not related to histopathologic type, differentiation grade, or tumour volume index in untreated malignant tumours. GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase. Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. No relation was found in untreated ovarian tumours between GST pi amount and response to platinum/cyclophosphamide chemotherapy. Thus, within the limitations of the current study no arguments were found for a role of GST in in vivo drug resistance of malignant ovarian tumours to platinum/cyclophosphamide chemotherapy.
Similar articles
-
Glutathione S-transferase expression in benign and malignant ovarian tumours.Br J Cancer. 1993 Aug;68(2):235-9. doi: 10.1038/bjc.1993.321. Br J Cancer. 1993. PMID: 8347477 Free PMC article.
-
Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome.Br J Cancer. 1996 Mar;73(6):763-9. doi: 10.1038/bjc.1996.133. Br J Cancer. 1996. PMID: 8611377 Free PMC article.
-
Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy.Br J Cancer. 1992 Nov;66(5):937-42. doi: 10.1038/bjc.1992.389. Br J Cancer. 1992. PMID: 1419640 Free PMC article.
-
Medical therapy of advanced malignant epithelial tumours of the ovary.Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
-
Glutathione S-transferase and drug resistance.Cancer Treat Res. 1989;48:171-87. doi: 10.1007/978-1-4613-1601-5_11. Cancer Treat Res. 1989. PMID: 2577137 Review.
Cited by
-
Human cell lines as models for multidrug resistance in solid tumours.Cytotechnology. 1993;12(1-3):231-56. doi: 10.1007/BF00744666. Cytotechnology. 1993. PMID: 7765327 Review.
-
Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.Br J Cancer. 1993 Jul;68(1):86-92. doi: 10.1038/bjc.1993.291. Br J Cancer. 1993. PMID: 8318426 Free PMC article.
-
Cisplatin nephrotoxicity: molecular mechanisms.Cancer Ther. 2003;1:47-61. Cancer Ther. 2003. PMID: 18185852 Free PMC article.
-
Overcoming drug resistance in ovarian carcinoma.Curr Oncol Rep. 2001 Jan;3(1):19-26. doi: 10.1007/s11912-001-0038-z. Curr Oncol Rep. 2001. PMID: 11123865 Review.
-
Expression patterns of carcinogen detoxifying genes (CYP1A1, GSTP1 & GSTT1) in HNC patients.Pathol Oncol Res. 2013 Jan;19(1):89-94. doi: 10.1007/s12253-012-9563-3. Epub 2012 Aug 25. Pathol Oncol Res. 2013. PMID: 22918668
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous